

## The Trendlines Group Reports Second Quarter 2019 Results

**Misgav, Israel and Singapore**, 7 August 2019 – The Trendlines Group Ltd. (the “**Company**” and together with its subsidiaries, “**Trendlines**” or the “**Group**”) (SGX: 42T; OTCQX: TRNLY), a leading Israel- and Singapore-based investment and innovation commercialization company focused on early-stage, high-growth, innovation-based medical and agricultural technologies, announced its financial results for the second quarter of 2019 ended 30 June 2019 (“**Q2 2019**”).

### Second Quarter 2019 Highlights

*As at 30 June 2019 unless otherwise noted*

#### Group Financials

- Fair value of portfolio: US\$95.6 million (31.12.18: US\$97.2 million)
- Total current assets: US\$8.9 million (31.12.18: US\$11.8 million)
- Book value: US\$84.4 million (31.12.18: US\$86.4 million)
- Operating general and administrative expenses: US\$1.7 million (Q2 2018: US\$1.6 million)
- Net loss: US\$1.4 million (Q2 2018: US\$1.8 million)

#### Q2 2019 Corporate/Business Developments

- Five Portfolio Companies awarded Horizon 2020 non-dilutive grants
- BioFishency Ltd. completed agreement with the Technion-Israel Institute of Technology for development of new aquaculture technology product line
- Limaca Medical Ltd. initiated FIH study of biopsy device for improved tumor diagnosis
- Hargol FoodTech Ltd. raised approximately US\$1.1 million
- InPlant Technologies Ltd. signed a joint development agreement with Johnson Matthey

#### Post Q2 2019 Developments

- Trendlines received US\$8 million investment from Librae Holdings Limited
- Trendlines received Stimatix GI Ltd. dividend distribution of US\$1.1 million
- A global investment company made a US\$5 million capital commitment to Trendlines Agrifood Pte. Ltd.
- Trendlines welcomed its newest agtech Portfolio Company, EcoPhage Ltd., the second investment by the Bayer Trendlines Ag Innovation Fund
- MetoMotion Ltd. received US\$1.5 million investment from a Netherlands-based strategic partner
- Prof. Mandeep R. Mehra and Prof Nir Uriel joined Leviticus Cardio Ltd.’s scientific advisory board

## Q2 2019 Financial Results

Commenting on Trendlines' second quarter results, Chairman and CEO Steve Rhodes said, "Our commitment to building the value of our Portfolio Companies is evident in the first half of 2019 with the completion of several significant capital raises for Portfolio Companies, and with more in discussion."

"We continue to monitor our operating and general expenses while working on strengthening the Company's balance sheet."

The fair value of Trendlines' portfolio was US\$95.6 million as at 30 June 2019 having decreased by approximately US\$1.6 million as compared to 31 December 2018. It should be noted that the portfolio value does not reflect all current Portfolio Companies due to consolidation of six Singapore-based Portfolio Companies that are treated as subsidiaries controlled by The Trendlines Group.

The changes in the value of our investments in Portfolio Companies were mainly due to:

- The write-off of one Portfolio Company during Q1 2019 amounting to approximately US\$0.7 million due to lack of funding in this company,
- an aggregate decrease of approximately US\$2.8 million in the overall fair value of several of our Portfolio Companies based on factors such as the completion of fund-raising exercises at less favorable terms to the company, each company's commercial and technological progress; and
- an aggregate net decrease of US\$1.1 million in the fair value of Stimatix GI due to the payment of a dividend in the same amount to Trendlines from Stimatix GI Ltd. during Q2 2019.

The decrease in investments in Portfolio Companies was offset by:

- An aggregate increase of approximately US\$2.0 million in the overall fair value of several of our Portfolio Companies based on factors such as the completion of fund-raising exercises at favorable terms to the company, each company's commercial and technological progress, and
- additional investments in Portfolio Companies in the amount of approximately US\$1.0 million.

Chairman and CEO Todd Dollinger commented, "In June, we announced that five Portfolio Companies received non-dilutive funding grants totaling approximately €8 million from Horizon 2020, indicating strong endorsement of their technological progress and promise. The grants affirm the companies' excellence and innovation in

their respective fields and provide funding to assist them in bringing their technologies to market.”

### **Fund-Raising Following the Close of Q2**

On 6 August 2019, Trendlines announced the completion of the placement of 103,619,048 new ordinary shares in the capital of the Company (“**Placement Shares**”) at a placement price of S\$0.1050 per Placement Share (“**Placement Price**”) to Librae Holdings Limited. The Placement Price represents a premium of 34.6% to the volume weighted average price of S\$0.0780 for each share, based on trades done on the shares on the Catalist of the SGX-ST for the full market day on 19 July 2019 (being the last full market day on which there were trades done on the shares prior to the date of the Subscription Agreement), resulting in gross proceeds of approximately S\$10.9 million (US\$8.0 million at the exchange rate of US\$1.00 = S\$1.360).

For full financial information, see our announcement to the SGX: Unaudited Financial Statements for the three months ended 30 June 2019.

Management will record a presentation of the financial results and business developments for the second quarter ended 30 June 2019, including responding to pre-submitted questions from analysts and investors. Questions regarding the Q2 2019 financial results can be sent to [shira@trendlines.com](mailto:shira@trendlines.com) up until 11:30 a.m. on 8 August 2019. The recording will be posted to Trendlines’ investors website on Thursday, 8 August 2019.

### **About The Trendlines Group Ltd.**

Trendlines is an innovation commercialization company that invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies to fulfill its mission to improve the human condition. As intensely hands-on investors, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Trendlines’ shares are traded on the Singapore Stock Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX International (OTCQX: TRNLY).

-The End-

### **Investor Contact Information**

Israel  
Shira Zimmerman, The Trendlines Group  
[shira@trendlines.com](mailto:shira@trendlines.com)  
Tel: +972.72.260.7000

Singapore  
Reyna MEI, Financial PR  
[reyna@financialpr.com.sg](mailto:reyna@financialpr.com.sg)  
Tel: +65.6438.2990

-----

This press release has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor") in accordance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalyst.

This press release has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms. Jennifer Tan, Associate Director, Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: [sponsorship@ppcf.com.sg](mailto:sponsorship@ppcf.com.sg))